Treatment Strategies and Clinical Trial Design in ADPKD

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

More frequent utilization and continuous improvement of imaging techniques has enhanced appreciation of the high phenotypic variability of autosomal dominant polycystic kidney disease, improved understanding of its natural history, and facilitated the observation of its structural progression. At the same time, identification of the PKD1 and PKD2 genes has provided clues to how the disease develops when they (genetic mechanisms) and their encoded proteins (molecular mechanisms) are disrupted. Interventions designed to rectify downstream effects of these disruptions have been examined in animal models, and some are currently tested in clinical trials. Efforts are underway to determine whether interventions capable to slow down, stop, or reverse structural progression of the disease will also prevent decline of renal function and improve clinically significant outcomes.

Original languageEnglish (US)
Pages (from-to)190-204
Number of pages15
JournalAdvances in Chronic Kidney Disease
Volume17
Issue number2
DOIs
StatePublished - Mar 2010

Fingerprint

Autosomal Dominant Polycystic Kidney
Natural History
Disease Progression
Animal Models
Observation
Clinical Trials
Kidney
Genes
Proteins

Keywords

  • ADPKD
  • Consortium for radiologic imaging study of PKD
  • Cyclic AMP
  • Mammalian target of rapamycin
  • Polycystic kidney disease
  • Somatostatin analogs
  • Vasopressin V2 receptor antagonist

ASJC Scopus subject areas

  • Nephrology

Cite this

Treatment Strategies and Clinical Trial Design in ADPKD. / Torres, Vicente.

In: Advances in Chronic Kidney Disease, Vol. 17, No. 2, 03.2010, p. 190-204.

Research output: Contribution to journalArticle

@article{c4629e3b92ad424fba6a69d3451ffdfe,
title = "Treatment Strategies and Clinical Trial Design in ADPKD",
abstract = "More frequent utilization and continuous improvement of imaging techniques has enhanced appreciation of the high phenotypic variability of autosomal dominant polycystic kidney disease, improved understanding of its natural history, and facilitated the observation of its structural progression. At the same time, identification of the PKD1 and PKD2 genes has provided clues to how the disease develops when they (genetic mechanisms) and their encoded proteins (molecular mechanisms) are disrupted. Interventions designed to rectify downstream effects of these disruptions have been examined in animal models, and some are currently tested in clinical trials. Efforts are underway to determine whether interventions capable to slow down, stop, or reverse structural progression of the disease will also prevent decline of renal function and improve clinically significant outcomes.",
keywords = "ADPKD, Consortium for radiologic imaging study of PKD, Cyclic AMP, Mammalian target of rapamycin, Polycystic kidney disease, Somatostatin analogs, Vasopressin V2 receptor antagonist",
author = "Vicente Torres",
year = "2010",
month = "3",
doi = "10.1053/j.ackd.2010.01.006",
language = "English (US)",
volume = "17",
pages = "190--204",
journal = "Advances in Chronic Kidney Disease",
issn = "1548-5595",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Treatment Strategies and Clinical Trial Design in ADPKD

AU - Torres, Vicente

PY - 2010/3

Y1 - 2010/3

N2 - More frequent utilization and continuous improvement of imaging techniques has enhanced appreciation of the high phenotypic variability of autosomal dominant polycystic kidney disease, improved understanding of its natural history, and facilitated the observation of its structural progression. At the same time, identification of the PKD1 and PKD2 genes has provided clues to how the disease develops when they (genetic mechanisms) and their encoded proteins (molecular mechanisms) are disrupted. Interventions designed to rectify downstream effects of these disruptions have been examined in animal models, and some are currently tested in clinical trials. Efforts are underway to determine whether interventions capable to slow down, stop, or reverse structural progression of the disease will also prevent decline of renal function and improve clinically significant outcomes.

AB - More frequent utilization and continuous improvement of imaging techniques has enhanced appreciation of the high phenotypic variability of autosomal dominant polycystic kidney disease, improved understanding of its natural history, and facilitated the observation of its structural progression. At the same time, identification of the PKD1 and PKD2 genes has provided clues to how the disease develops when they (genetic mechanisms) and their encoded proteins (molecular mechanisms) are disrupted. Interventions designed to rectify downstream effects of these disruptions have been examined in animal models, and some are currently tested in clinical trials. Efforts are underway to determine whether interventions capable to slow down, stop, or reverse structural progression of the disease will also prevent decline of renal function and improve clinically significant outcomes.

KW - ADPKD

KW - Consortium for radiologic imaging study of PKD

KW - Cyclic AMP

KW - Mammalian target of rapamycin

KW - Polycystic kidney disease

KW - Somatostatin analogs

KW - Vasopressin V2 receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=77249163235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249163235&partnerID=8YFLogxK

U2 - 10.1053/j.ackd.2010.01.006

DO - 10.1053/j.ackd.2010.01.006

M3 - Article

C2 - 20219622

AN - SCOPUS:77249163235

VL - 17

SP - 190

EP - 204

JO - Advances in Chronic Kidney Disease

JF - Advances in Chronic Kidney Disease

SN - 1548-5595

IS - 2

ER -